UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

FAK signaling in human cancer as a target for therapeutics

Pharmacology & therapeutics (Oxford), 2015-02, Vol.146, p.132-149

2015

Volltextzugriff (PDF)

CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment

European journal of medicinal chemistry, 2023-01, Vol.245 (Pt 1), p.114884-114884, Article 114884

2023

Volltextzugriff (PDF)

Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience

Hematological oncology, 2021-10, Vol.39 (4), p.549-557

2021

Volltextzugriff (PDF)

Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Expert opinion on drug metabolism & toxicology, 2024-04, Vol.20 (4), p.207-224

2024

Volltextzugriff (PDF)

Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

Hematology (Luxembourg), 2022-12, Vol.27 (1), p.1171-1175

2022

Volltextzugriff (PDF)

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study

Cancer science, 2024-08, Vol.115 (8), p.2751-2761

2024

Volltextzugriff (PDF)

CML 25 Years Later - Poised for Another Breakthrough?

The New England journal of medicine, 2024-09, Vol.391 (10), p.955-957

Abruzzese, Elisabetta

2024

Volltextzugriff (PDF)

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review

JAMA : the journal of the American Medical Association, 2023-03, Vol.329 (11), p.918

Shadman, Mazyar

2023

Volltextzugriff (PDF)

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

Cancer science, 2019-10, Vol.110 (10), p.3255-3266

2019

Volltextzugriff (PDF)

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

Clinical lung cancer, 2022-01, Vol.23 (1), p.e69-e82

2022

Volltextzugriff (PDF)

Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors

Hepatology international, 2023-04, Vol.17 (2), p.281-290

2023

Volltextzugriff (PDF)

A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction

Biological trace element research, 2023-12, Vol.201 (12), p.5540-5545

2023

Volltextzugriff (PDF)

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

British journal of haematology, 2022-01, Vol.196 (1), p.70-78

2022

Volltextzugriff (PDF)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Cancer science, 2016-08, Vol.107 (8), p.1134-1140

2016

Volltextzugriff (PDF)

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

The New England journal of medicine, 2024-09, Vol.391 (10), p.885-898

2024

Volltextzugriff (PDF)

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

Cancer medicine (Malden, MA), 2024-04, Vol.13 (8), p.e7208-n/a

2024

Volltextzugriff (PDF)

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor

Multiple sclerosis, 2023-10, Vol.29 (11-12), p.1471-1481

2023

Volltextzugriff (PDF)

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

European journal of medicinal chemistry, 2024-09, Vol.275, p.116558, Article 116558

2024

Volltextzugriff (PDF)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML

Cancer science, 2023-03, Vol.114 (3), p.995-1006

2023

Volltextzugriff (PDF)

Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer

International journal of urology, 2024-05, Vol.31 (5), p.465-474

2024

Volltextzugriff (PDF)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Scientific reports, 2023-11, Vol.13 (1), p.19729-19729, Article 19729

2023

Volltextzugriff (PDF)

Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK

The journal of physical chemistry. B, 2024-03, Vol.128 (12), p.2874-2884

2024

Volltextzugriff (PDF)

Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance

Investigational new drugs, 2024-06, Vol.42 (3), p.335-339

2024

Volltextzugriff (PDF)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure

Cancer science, 2016-07, Vol.107 (7), p.1001-1005

2016

Volltextzugriff (PDF)

Tyrosine kinase inhibitor therapy in pediatric sarcoma: Prognostic implications of pulmonary metastatic cavitation

Pediatric blood & cancer, 2023-11, Vol.70 (11), p.e30629-e30629

2023

Volltextzugriff (PDF)

1 – 25 von 41.388

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38.523)
Mit Volltextzugriff
(35.987)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(35.195)
Life Sciences & Biomedicine
(33.132)
Humans
(26.333)
Animals
(14.280)
Oncology
(13.075)
Protein-Tyrosine Kinases - Antagonists & Inhibitors
(9.746)
Kinases
(8.211)
Male
(7.506)
Female
(7.465)
Phosphorylation
(7.006)
Biological And Medical Sciences
(6.866)
Mice
(6.863)
Biochemistry & Molecular Biology
(6.295)
Mutation
(6.166)
Tyrosine Kinase Inhibitors
(6.054)
Protein Kinase Inhibitors - Therapeutic Use
(5.919)
Tyrosine
(5.844)
Protein Kinase Inhibitors - Pharmacology
(5.824)
Pharmacology & Pharmacy
(5.496)
Protein-Tyrosine Kinases - Metabolism
(5.481)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(33.937)
EZB Electronic Journals Library
(23.141)
IngentaConnect
(18.298)
Journals@Ovid
(13.552)
IngentaConnect Journals
(9.758)
NUS Single-Journal Subscriptions
(7.863)
Elsevier ScienceDirect Journals Complete
(7.693)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(5.937)
Wiley Online Library - AutoHoldings Journals
(5.320)
SpringerLink
(4.097)
Wiley Online Library Full Collection 2018
(3.814)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(2.644)
Nature Journals
(2.541)
Taylor & Francis Journals Auto-Holdings Collection
(2.460)
Taylor & Francis Current Content Access
(2.107)
Nexis Uni
(2.086)
Taylor & Francis Journals Complete
(1.384)
Oxford journals
(957)
SAGE Publications
(647)
JSTOR All Journals
(630)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Journal Of Biological Chemistry
(1.203)
Journal Of Biological Chemistry/the journal Of Biological Chemistry
(951)
Plos One
(805)
Oncogene
(637)
Biochemical And Biophysical Research Communications
(511)
Cancers
(499)
Blood
(497)
The Journal Of Immunology
(490)
Leukemia
(467)
The journal Of Immunology/the journal Of Immunology
(423)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

FAK signaling in human cancer as a target for therapeutics

CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment

Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience

Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma

Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study

CML 25 Years Later - Poised for Another Breakthrough?

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review

Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations

Comparison of hepatitis B virus reactivation in hepatocellular carcinoma patients who received tyrosine kinase inhibitor alone or together with programmed cell death protein-1 inhibitors

A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML

Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor‐targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

Molecular Insights into the Impact of Mutations on the Binding Affinity of Targeted Covalent Inhibitors of BTK

Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure

Tyrosine kinase inhibitor therapy in pediatric sarcoma: Prognostic implications of pulmonary metastatic cavitation

Suchergebnisse filtern